RICHLAND, Wash.--(BUSINESS WIRE)--IsoRay, Inc. (“IsoRay”) (OTCBB:ISRY), the medical technology company focusing on innovative treatments for solid cancer tumors using its proprietary Cesium-131 initially in brachytherapy seeds, announced today that all warrants that were called on February 21, 2006, were exercised prior to the call date of March 26, 2007, and thus raised an additional $4,989,000 of capital. The August financing was led by MicroCapital LLC.
